Celebrating 100 Years of Jonas Salk by the Forward

Celebrating 100 Years of Jonas Salk

Happy birthday Jonas Salk!

Today’s Google Doodle pays tribute to the Jewish inventor of the polio vaccine, born 100 years ago today in New York City. Been a long time since high school science class? Here’s a little refresher:

Who Is Jonas Salk

Jonas Salk 1914, New York City - 1995, San Diego) graduated from New York University with a medical degree in 1939. His parents, Jewish Ashkenazi immigrants with little formal education, were eager to see their children succeed. Salk first worked on developing an influenza vaccination before becoming interested in the polio virus. He developed a vaccination which used dead virus, also known as inactivated polio vaccine (IPV). The field trial for the vaccine was one of the largest of its kind, with over 600,000 schoolchildren injected with the vaccine or a placebo, and a million more serving as “observed” controls. In 1955, the vaccine, which showed 90% effectiveness, was approved to international acclaim. He continued his biomedical research in the Salk Institute for Biological Sciences, which he founded in San Diego, Ca., focusing on multiple sclerosis and HIV.

About Polio

The polio virus is transmitted through water and faeces, where it can remain infectious for a long period of time, and causes paralysis. Children are especially vulnerable. Today, it’s easy to forget the terror caused by polio epidemics. In 2009, a PBS documentary declared that, “Apart from the atomic bomb, America’s greatest fear was polio.” In the 1950s, between 25,000 and 50,000 new cases of polio were diagnosed every year in the United States alone. When news that Salk’s vaccine testing was successful went public in 1955, he was hailed as a “miracle maker.”) In fact, April 12, 1955 almost became a national holiday . The last U.S. polio case was reported in 1979.

The Vaccine

Salk’s vaccine uses dead polio viruses, grown on monkey kidney and then inactivated with formaldehyde. The main disadvantage of the inactivated polio vaccine (IPV) is that the immunization is not life-long. Albert Sabin, another member of the tribe, developed an oral polio vaccine around the same time, which uses live viruses and digested orally, making it cheaper and easier administrate. Immunization is life-long, but the vaccination carries a small risk of infection, especially in people with compromised immune systems. In 2000, the U.S. government switched back to recommending the use of Salk’s vaccine because the risks associated with Sabin’s oral vaccine, which outweighed the cost benefits.


Anna Goldenberg

Anna Goldenberg

Anna Goldenberg was the Forward’s culture fellow.

Celebrating 100 Years of Jonas Salk

Your Comments

The Forward welcomes reader comments in order to promote thoughtful discussion on issues of importance to the Jewish community. All readers can browse the comments, and all Forward subscribers can add to the conversation. In the interest of maintaining a civil forum, The Forward requires that all commenters be appropriately respectful toward our writers, other commenters and the subjects of the articles. Vigorous debate and reasoned critique are welcome; name-calling and personal invective are not and will be deleted. Egregious commenters or repeat offenders will be banned from commenting. While we generally do not seek to edit or actively moderate comments, our spam filter prevents most links and certain key words from being posted and the Forward reserves the right to remove comments for any reason.

Recommend this article

Celebrating 100 Years of Jonas Salk

Thank you!

This article has been sent!